Stoke Looks to Pivotal Trial for Dravet Candidate

Stoke Therapeutics is gearing up for a Phase III trial studying its lead candidate in children with Dravet syndrome after announcing positive results from a Phase I/IIa study Monday.

Stoke's STK-001 targets the haploinsufficiency of the SCN1A gene and, if approved, could be the first therapeutic to address the root cause of Dravet syndrome.